Validation of Russian version of Amyotrophic Lateral Sclerosis Impairment Multidomain Scale
https://doi.org/10.30629/2658-7947-2024-29-6-27-34
Abstract
Motor impairment, bulbar palsy and respiratory insufficiency represent main presentation of amyotrophic lateral sclerosis (ALS). The rate of symptom worsening reflects progression of the disease.
The objective: to analyze the reliability of the Russian-language version of the “ALS Impairment Multi-Domain Scale” (AIMS).
Material and methods. The study was conducted on a sample of 50 people with ALS. The reliability of the scale was analyzed, including internal consistency, retest and inter-expert reliability, and convergent validity in relation to ALS Functional Rating Scale — Revised (ALSFRS-R).
Results. AIMS has demonstrated excellent internal consistency, high retest and inter-expert reliability, and convergent validity. Compared with the ALSFRS-R, AIMS had smaller ceiling and floor effects.
Conclusion. The Russian-language version of AIMS is a reliable tool for the evaluation of severity of neurological deficit in patients with ALS and for the assessment of the disease progression rate.
Supporting agencies: This work was supported by the Bashkir State Medical University Strategic Academic Leadership Program (PRIORITY-2030).
About the Authors
E. V. Pervushina
Bashkir State Medical University
Russian Federation
Russian Federation
Ufa
M. A. Kutlubaev
Bashkir State Medical University
Russian Federation
Russian Federation
Ufa
L. A. Smakova
Institute of Biochemistry and Genetics of Ufa Federal Scientifi c Center
Russian Federation
Russian Federation
Ufa
References
1. Nguyen L. Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis. Cells. 2024;13(11):888. https://doi.org/10.3390/cells13110888
2. Kutlubaev MA. Promising approaches to the pathogenetic therapy of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):13–21. (In Russ.). https://doi.org/10.17116/jnevro202412404113
3. Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996;53(2):141–7.
4. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1-2):13–21. https://doi.org/10.1016/s0022-510x(99)00210-5
5. Brylev L, Demeshonok VS, Ataulina AI, Kovalchuk MO, Druzhinin DS, Guekht AB. Validity and reliability of the Russian version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Neurol Sci. 2024;45(1):187–189. https://doi.org/10.1007/s10072-023-06979-3
6. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci. 1997;152(1):1–9. https://doi.org/10.1016/s0022-510x(97)00237-2.
7. de Jongh AD, van Eijk RPA, Bakker LA, Bunte TM, Beelen A, van der Meijden C, van Es MA, Visser-Meily JMA, Kruitwagen ET, Veldink JH, van den Berg LH. Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS. Neurology.2023;101(6):e602-e612. https://doi.org/10.1212/WNL.0000000000207483
8. Turner MR; UK MND Clinical Studies Group. Diagnosing ALS: the Gold Coast criteria and the role of EMG. Pract Neurol. 2022;22(3):176–178. https://doi.org/10.1136/practneurol-2021-003256
9. Balendra R, Al Khleifat A, Fang T, Al-Chalabi A. A standard operating procedure for King’s ALS clinical staging. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):159–164. https://doi.org/10.1080/21678421.2018.1556696
10. Boateng GO, Neilands TB, Frongillo EA, Melgar-Quiñonez HR, Young SL. Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer. Front Public Health. 2018;6:149. https://doi.org/10.3389/fpubh.2018.0014
11. Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, Yu H, Wymer J, Cudkowicz M, Macklin EA, Schoenfeld D, Pattee G. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics. 2017;14(3):762–772. doi: 10.1007/s13311-016-0508-5. Erratum in: Neurotherapeutics. 2017;14(3):830. https://doi.org/10.1007/s13311-017-0517-z
12. Huang SL, Shen YL, Peng WY, Ye K, Zheng H. Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta Neurol Belg. 2024;124(3):895–904. https://doi.org/10.1007/s13760-024-02476-2
13. Kutlubaev MA, Areprintceva DK, Pervushina EV, Brylev LV. Cognitive disorders in amyotrophic lateral sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):68–74. (In Russ.) https://doi.org/10.14412/2074-2711-2023-2-68-74
14. Kutlubaev MA, Caga J, Xu Y, Areprintseva DK, Pervushina EV, Kiernan MC. Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(1–2):14–23. https://doi.org/10.1080/21678421.2022.2053721
Review
For citations:
Pervushina E.V., Kutlubaev M.A., Smakova L.A. Validation of Russian version of Amyotrophic Lateral Sclerosis Impairment Multidomain Scale. Russian neurological journal. 2024;29(6):27-34. (In Russ.) https://doi.org/10.30629/2658-7947-2024-29-6-27-34
Views:
279
Email this article 